Qiagen

Qiagen

Qiagen was founded in 1984 by Metin Colpan and Peer Schatz, who grew the firm from a Hilden-based startup into a publicly traded provider of sample and assay technologies. The company now supports over 500,000 customers across life sciences and clinical laboratories, with corporate headquarters in Venlo, Netherlands and operational headquarters in Hilden, Germany. Qiagen deploys capital across the molecular diagnostics value chain — from sample preparation and assay design to bioinformatics interpretation. Its portfolio spans infectious disease testing, oncology companion diagnostics, and next-generation sequencing workflows. Confirmed investment interests include precision medicine platforms and digital health infrastructure, with strategic partnerships extending to transplant monitoring and latent tuberculosis screening. The firm maintains manufacturing and R&D hubs in Europe, North America, and the United Kingdom. As of mid-2026, Qiagen employs a global workforce of over 6,000, with additional offices in Germantown, Maryland and Manchester, UK. The company anchors its corporate citizenship through the Qiagen Global Public Health Task Force and the Dutch-registered Stichting Qiagen foundation. In operational developments, Qiagen has continued to expand its QuantiFERON franchise and syndromic testing platforms, though specific deployment figures remain undisclosed. Qiagen differs from a conventional asset manager by embedding its investment function within an operating diagnostics company. This structure ties capital allocation directly to the firm's own R&D pipeline and commercial infrastructure, creating an internal feedback loop between product development and strategic investing that pure financial sponsors cannot replicate.